RxDoctor Payments Data

Rita Hamilton, DO

Physical Medicine & Rehabilitation · Dallas, TXNPI 1730197450

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 41.5% of the total.

$1,164in general payments, 2019–2025

Across 38 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$483
  • AbbVie$178
  • Lifeward, Inc.$165
  • Merz North America, Inc.$139
  • Medtronic$45
  • Rochester Medical Corporation$37
  • plus $117 from 5 others
$62,828in research payments, 2019–2025

Across 8 payments — averaging $7853.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mitsubishi Tanabe Pharma Development America, Inc.$27K
  • Vertex$25K
  • Tanabe Pharma America, Inc.$11K

What the payments were for

  • Food & beverage$1,14198%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Biopharmaceuticals, Inc18$483
AbbVie(2 entities)8$178
Lifeward, Inc.1$165
Merz North America, Inc.1$139
Medtronic2$45
Rochester Medical Corporation2$37
Coloplast2$35
Ossur Americas, Inc.1$27
180 Medical, Inc.1$22
Merz Pharmaceuticals, LLC1$21
Amneal Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,164 in reported general payments places this provider in the 75th percentile of 651 physical medicine & rehabilitation providers in Texas.

See all physical medicine & rehabilitation providers in Texas

Medicare billing

Part B allowed, 2024
$26,616
Medicare patients
181
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen345$19,069
Baclofen370$11,183
Gabapentin292$6,951
Pregabalin130$4,091
OxycontinOxycodone Hcl11$3,893
Tizanidine Hcl147$2,709
Oxybutynin Chloride41$1,413
Alprazolam139$1,233
Methenamine Hippurate18$1,222
Oxycodone Hcl68$1,198
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen34$1,166
Fentanyl11$1,026
Solifenacin Succinate20$982
Oxybutynin Chloride ErOxybutynin Chloride28$927
Midodrine Hcl20$876

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →